Anesthesia · Pain ManagementTrial Updateclinicalmid-term

Study on Ketamine vs Fentanyl for Pain Management in Laparoscopic Cholecystectomy

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/27/2026, 6:31:05 AM

Assessment confidence: 58% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

This clinical trial could significantly impact postoperative pain management protocols, potentially favoring ketamine over traditional analgesics like fentanyl. A shift in clinical practice could alter market dynamics and influence the competitive landscape for pain management solutions. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 12 ranked evidence items (4 high-relevance).

Strategic Assessment

If ketamine proves more effective, it may shift clinical practice towards its use, affecting sales of current analgesics like fentanyl. The strongest clinical anchor is Oropharyngeoesophageal Topical Anesthesia Versus Intravenous Propofol -Ketamine Sedation for Upper Gastrointestinal Endoscopy (ClinicalTrials.gov), sub-indication match (pain); entity match (ketamine). In pain, 4 regulatory and 0 competitive items passed relevance filtering for ketamine.

Competitive Pressure

The most relevant competitive pressure comes from This study could influence pain management protocols in surgical settings, potentially impacting the use of existing analgesics and the market for postoperative pain management solutions..

Regulatory Outlook

Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). Relevant agencies in corpus: FDA, MHRA. The trial's outcomes are unlikely to directly influence regulatory approvals but may inform future clinical guidelines and best practices.

Key Opportunities

If ketamine is proven more effective, it may lead to decreased sales of existing analgesics, affecting market share for companies involved in postoperative pain management.
Upside for ketamine may improve if Oropharyngeoesophageal Topical Anesthesia Versus Intravenous Propofol -Ketamine Sedation for Upper Gastrointestinal Endoscopy (ClinicalTrials.gov) delivers favorable follow-through.
If ketamine proves more effective, it may shift clinical practice towards its use, affecting sales of current analgesics like fentanyl.

What Would Change This Assessment

This becomes more urgent if Monitor results of the trial for efficacy data and subsequent changes in clinical guidelines for postoperative pain management.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAhigh relevance
Sub-indication match (pain)
FDA document
View source
FDA AP — FENTANYL-75 (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FENTANYL-37 (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management
MHRAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source

Oropharyngeoesophageal Topical Anesthesia Versus Intravenous Propofol -Ketamine Sedation for Upper Gastrointestinal Endoscopy
ClinicalTrials.govhigh relevance
Sub-indication match (pain); Entity match (ketamine)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Intraperitoneal Ketamine Versus Fentanyl as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy
ClinicalTrials.govmedium relevance
Entity match (ketamine); Patient population match (adjuvant)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govmedium relevance
Entity match (bupivacaine)
FDA document
View source
Impact of Bupivacaine Dilution With Dextrose or Saline on Infraclavicular Block Outcomes
ClinicalTrials.govmedium relevance
Entity match (bupivacaine)
FDA document
View source
Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

AstraZeneca's Elecoglipron Phase III Trials Target Obesity and T2DM
Humanexa Signalslow relevance
Sponsor/company relevance (AstraZeneca)
UK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Phase 3 Study of Radiprodil in GRIN-related Neurodevelopmental Disorder Initiated
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effect of different liposomal bupivacaine concentrations in ultrasound-guided superior trunk block on postoperative analgesia and mobility: a randomized double-blind controlled trial protocol for shou
PubMedhigh relevance
Sub-indication match (pain); Entity match (bupivacaine)
FDA document
View source
Thoracic paravertebral block with different doses of liposomal bupivacaine versus ropivacaine for postoperative analgesia in single-port thoracoscopic lung surgery: a randomized clinical trial.
PubMedhigh relevance
Sub-indication match (pain); Entity match (bupivacaine)
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Development and Preliminary Clinical Evaluation of Multifunctional Operative Support Arm in Reproductive Laparoscopic Surgery: A Randomized Controlled Study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The Effect of Moxibustion at the Dazhui Point on Hypothermia and Maternal Comfort During Cesarean Delivery: A Randomized Controlled Trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

ketamine
bupivacaine

Commercial impact

medium

If ketamine is proven more effective, it may lead to decreased sales of existing analgesics, affecting market share for companies involved in postoperative pain management.

Regulatory impact

low

The trial's outcomes are unlikely to directly influence regulatory approvals but may inform future clinical guidelines and best practices.

What to watch

Monitor results of the trial for efficacy data and subsequent changes in clinical guidelines for postoperative pain management.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.